Acelrx pharmaceuticals announces divestment of dsuvia® to alora pharmaceuticals

Agreement with alora pharmaceuticals provides acelrx with 15% royalties on commercial sales, 75% royalties on department of defense (dod) sales, up to $116.5 million in potential sales-based milestone payments, and a strong commercial partner experienced with commercialization in hospital settings divestment allows acelrx to prioritize resources on its late stage development assets, led by niyad™, the lead nafamostat program with breakthrough device designation status from fda near-term corporate milestones expected by the end of q2 2023 include the niyad emergency use authorization submission and the filing of a new drug application for the first of our two pre-filled syringe product candidates hayward, calif. , march 14, 2023 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the divestment of its fda-approved drug, dsuvia® to alora pharmaceuticals (alora).
ACRX Ratings Summary
ACRX Quant Ranking